Trastuzumab: all 614 studies that test it
Page 5 of 7. Open to participants first (88), then studies with results posted, then the rest; newest registration first within each.
- A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male VolunteersCompletedNCT03180242Phase 1
- Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.Active, not recruitingNCT03161353Phase 2
- Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsStatus unknownNCT03144947Phase 2
- Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabCompletedNCT03135171Phase 1
- Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerActive, not recruitingNCT03125928Phase 2
- Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLMStatus unknownNCT03125161Phase 3
- A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs HerceptinStatus unknownNCT03085368Phase 2/3
- A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer PatientsCompletedNCT03013504Phase 3
- Pembrolizumab, Trastuzumab, HER2 Positive Gastric CancerStatus unknownNCT02901301Phase 1/2
- Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric CancerStatus unknownNCT02805829Phase 1/2
- A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)CompletedNCT02738970Phase 1
- Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal CancerCompletedNCT02725424Phase 2
- Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)CompletedNCT02705859Phase 1
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerStatus unknownNCT02689921Phase 2
- Denosumab as an add-on Neoadjuvant Treatment (GeparX)CompletedNCT02682693Phase 2
- Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed HerceptinCompletedNCT02665637Phase 1
- Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCompletedNCT02649686Phase 1
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)CompletedNCT02627274Phase 1
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast CancerTerminatedNCT02598427Phase 1
- Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerTerminatedNCT02598310Phase 2
- Phase 1 Study of Trastuzumab Administered as a Single Intravenous InfusionCompletedNCT02594761Phase 1
- Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+TerminatedNCT02593708Phase 1
- Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast CancerWithdrawnNCT02569489Phase 1
- A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerCompletedNCT02488564Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or BevacizumabActive, not recruitingNCT02436993Phase 2
- Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver MetastasisStatus unknownNCT02380131Phase 4
- A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCISWithdrawnNCT02336984Phase 1/2
- Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- TumorsCompletedNCT02307227Phase 2
- T- XELOX in HER2-positive Stage III Gastric Cancer After D2 GastrectomyStatus unknownNCT02250209Phase 2
- Neoadjuvant Trastuzumab and Letrozole for Postmenopausal WomenStatus unknownNCT02214004Phase 2
- Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02205047Phase 2
- Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerCompletedNCT02167854Phase 1
- Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsCompletedNCT02152943Phase 1
- Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal CarcinomaCompletedNCT02120911Phase 1/2
- Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast CancerWithdrawnNCT02102438Not applicable
- Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male AdultsCompletedNCT02100917Phase 1
- Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerCompletedNCT02060253Phase 1
- A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC ParticipantsCompletedNCT02040935Phase 3
- NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric CancerStatus unknownNCT02030561Phase 1/2
- A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerCompletedNCT02025192Phase 1
- A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)CompletedNCT02015156Phase 1
- Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerCompletedNCT02004769Phase 2
- First-in-Human Dose Escalation Trial in Subjects With Advanced MalignanciesCompletedNCT01971515Phase 1
- A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast CancerCompletedNCT01964391Phase 3
- Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + LapatinibCompletedNCT01875666Early Phase 1
- Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial CarcinomaCompletedNCT01828736Phase 2
- A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 YearsCompletedNCT01810393Phase 3
- Pre Operative Trastuzumab in Operable Breast CancerTerminatedNCT01785420Phase 3
- A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction CancerCompletedNCT01748773Phase 2
- A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerCompletedNCT01746771Phase 1/2
- A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerCompletedNCT01736410Phase 2
- Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"Status unknownNCT01641406Phase 2
- A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)CompletedNCT01603264Phase 1
- Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric CancerCompletedNCT01602406Phase 1
- Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1CompletedNCT01597414Phase 2
- Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing ChemotherapyCompletedNCT01594177Phase 2
- Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast CancerWithdrawnNCT01557764Phase 2
- Efficacy Study of Herceptin to Treat HER2-negative CTC Breast CancerCompletedNCT01548677Phase 2
- Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)PositiveCompletedNCT01503983Phase 2
- A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.CompletedNCT01485926Phase 2
- GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain MetastasesCompletedNCT01480583Phase 2
- Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on TrastuzumabWithdrawnNCT01479179Phase 1/2
- Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or StomachCompletedNCT01472029Phase 2
- Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsCompletedNCT01454804Phase 1
- Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyCompletedNCT01434303Phase 1
- Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's DiseaseWithdrawnNCT01427244Phase 2
- Weekly Paclitaxel and Trastuzumab in Metastatic Breast CancerCompletedNCT01423695Phase 2
- Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast CancerCompletedNCT01423123Phase 1
- Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive PatientsTerminatedNCT01402401Phase 2
- Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOXCompletedNCT01396707Phase 2
- Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast CancerCompletedNCT01387373Phase 2
- Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio ImmunotherapyCompletedNCT01384253Phase 1
- Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous MeningitisCompletedNCT01373710Phase 1/2
- A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast CancerCompletedNCT01367028Phase 2
- A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric CancerCompletedNCT01364493Phase 2
- Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric CancerStatus unknownNCT01359397Phase 2
- A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld SyringeCompletedNCT01344863Phase 1
- Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast CancerCompletedNCT01340430Phase 2
- Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast CancerStatus unknownNCT01321775Phase 2
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerStatus unknownNCT01304797Phase 1
- A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedNCT01304784Phase 1
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast CancerCompletedNCT01300962Phase 1
- Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable CancerCompletedNCT01295086Not applicable
- A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompletedNCT01285466Phase 1
- Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With TrastuzumabCompletedNCT01271920Phase 1/2
- Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerTerminatedNCT01254136Phase 1/2
- Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast CancerCompletedNCT01242449Phase 2
- Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast CancerStatus unknownNCT01170143Phase 2
- A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast CancerWithdrawnNCT01137994Phase 2
- Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast CancerActive, not recruitingNCT01104571Phase 3
- A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast CancerCompletedNCT00960960Phase 1
- Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow MicrometastasesCompletedNCT00949247Early Phase 1
- Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast CancerCompletedNCT00943410Phase 2
- Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedNCT00928330Phase 1
- Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With GemcitabineCompletedNCT00923299Phase 1/2
- Trastuzumab in Treating Women With Metastatic Breast CancerCompletedNCT00896376Not applicable